AVALO THERAPEUTICS, INC. Payment for Contingent Consideration Liability, Financing Activities
AVALO THERAPEUTICS, INC. (AVTX) reported Payment for Contingent Consideration Liability, Financing Activities of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities · last filed 2021-03-08
- AVALO THERAPEUTICS, INC. payment for contingent consideration liability, financing activities for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- AVALO THERAPEUTICS, INC. payment for contingent consideration liability, financing activities for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- AVALO THERAPEUTICS, INC. payment for contingent consideration liability, financing activities for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- AVALO THERAPEUTICS, INC. payment for contingent consideration liability, financing activities for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- AVALO THERAPEUTICS, INC. payment for contingent consideration liability, financing activities for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- AVALO THERAPEUTICS, INC. payment for contingent consideration liability, financing activities for fiscal 2019 was $881.93K, a 199.53% increase from fiscal 2018.
- AVALO THERAPEUTICS, INC. payment for contingent consideration liability, financing activities for fiscal 2018 was $294.44K.
- AVALO THERAPEUTICS, INC. payment for contingent consideration liability, financing activities for fiscal 2017 was $0.00.
| Period end | Payment for Contingent Consideration Liability, Financing Activities 3 month | Payment for Contingent Consideration Liability, Financing Activities 6 month | Payment for Contingent Consideration Liability, Financing Activities 9 month | Payment for Contingent Consideration Liability, Financing Activities 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $0.00 derived: sum of 2 quarters · filed 2021-03-08 | $0.00 derived: sum of 3 quarters · filed 2021-03-08 | $0.00 10-K · filed 2021-03-08 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | $314.02K derived: sum of 4 quarters · filed 2021-03-08 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $314.02K derived: sum of 3 quarters · filed 2021-03-08 | $502.68K derived: sum of 4 quarters · filed 2021-03-08 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | $314.02K derived: sum of 2 quarters · filed 2021-03-08 | $502.68K derived: sum of 3 quarters · filed 2021-03-08 | $653.25K derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-12-31 | $314.02K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $502.68K derived: sum of 2 quarters · filed 2021-03-08 | $653.25K derived: sum of 3 quarters · filed 2021-03-08 | $881.93K 10-K · filed 2021-03-08 |
| 2019-09-30 | $188.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $339.23K derived: sum of 2 quarters · filed 2020-11-09 | $567.91K 10-Q · filed 2020-11-09 | $725.34K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $150.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $379.25K 10-Q · filed 2020-08-06 | $536.68K derived: sum of 3 quarters · filed 2020-08-06 | $673.69K derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $228.68K 10-Q · filed 2020-05-07 | $386.11K derived: sum of 2 quarters · filed 2020-05-07 | $523.11K derived: sum of 3 quarters · filed 2020-05-07 | $523.11K derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $157.43K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $294.44K derived: sum of 2 quarters · filed 2020-03-11 | $294.44K derived: sum of 3 quarters · filed 2020-03-11 | $294.44K 10-K · filed 2020-03-11 |
| 2018-09-30 | $137.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $137.01K derived: sum of 2 quarters · filed 2019-11-14 | $137.01K 10-Q · filed 2019-11-14 | $137.01K derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | $0.00 derived: sum of 3 quarters · filed 2019-08-08 | |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | $0.00 derived: sum of 2 quarters · filed 2019-05-09 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $0.00 10-K · filed 2019-03-18 | ||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |